摘要 |
Deoxyribonuclase 1-like 3 (D3) hydrolyzes lipid-complexed DNA and decreases transfection efficiency in liposomal transfection (lipofection) Systems. Accordingly, D1L3 provides a more accurate test of the efficiency of lipid/liposomal based gene therapy than current standards using deoxyribonuclease 1 (D1). Moreover, it has been found that mice with systemic lupus erythematosus (lupus) have lowered D1L3 activity. Therefore, differing therapeutic benefits may result from either the upward or downward therapeutic regulation of D1L3 activity. For example, blocking D1L3 activity enhances liposomal transfection for gene therapy, while increasing D1L3 activity may enhance destruction of pathogenic DNA, whether viral, bacterial or endogenous. Destruction of pathogenic DNA may provide treatment for lupus, or viral and oncogenic diseases.
|